Dr. Michael Foggs: February 15, 2016

Dr-Michael-Foggs

EXPERT DISCUSSES PERSISTENT ASTHMA SYMPTOMS AND NEW CLASS OF TREATMENT

New maintenance therapy works differently to help people with asthma breathe better

Dr. Michael Foggs – Chief of Allergy and Immunology, Advocate Medical Group of Advocate Health Care in Chicago, is available on February 15 to educate your listeners about recognizing uncontrolled asthma symptoms and this new treatment option for patients with asthma.

 

More than 22 million people in the U.S. suffer from asthma. Despite other currently available treatments, people with asthma continue to experience symptoms, including coughing, wheezing, and shortness of breath. One survey found about 55 percent of asthma patients taking a treatment still remained uncontrolled.

Recently, the FDA approved SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray as the first new class of inhaled medicine approved for asthma in over 10 years. SPIRIVA RESPIMAT is steroid-free and works differently than other treatments currently on the market.

When asthma symptoms continue despite taking a daily maintenance treatment, the addition of SPIRIVA RESPIMAT, by helping relax the airways in the lungs, has been proven to help people breathe better and reduce flare ups (also known as exacerbations). SPIRIVA RESPIMAT 2.5 µg (delivered in 2 puffs of 1.25 µg each) is indicated for the long-term, once-daily, prescription maintenance treatment of asthma in people ages 12 years and older. SPIRIVA RESPIMAT is not a treatment for sudden asthma symptoms. In the treatment of asthma, the maximum benefits in lung function may take up to 4 to 8 weeks of dosing.

Tiotropium, the active ingredient in SPIRIVA, has been used for more than 10 years as a maintenance treatment for chronic obstructive pulmonary disease (COPD) and has extensive clinical experience in COPD.

MORE ABOUT DR. MICHAEL FOGGS:
Dr. Michael Foggs is Chief of Allergy and Immunology at Advocate Medical Group of Advocate Health Care. He has practiced and conducted clinical research in allergy and immunology for over 30 years.  Dr. Foggs recently served as president of the American College of Allergy, Asthma & Immunology and president of the American Association of Certified Allergists and Immunology.

Speak Your Mind

*